{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:24:40Z","timestamp":1783081480359,"version":"3.54.6"},"reference-count":59,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T00:00:00Z","timestamp":1782950400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"PTC Therapeutics Germany GmbH","award":["PTC Therapeutics Germany GmbH"],"award-info":[{"award-number":["PTC Therapeutics Germany GmbH"]}]},{"name":"PTC Therapeutics Germany GmbH","award":["PTC Therapeutics Germany GmbH"],"award-info":[{"award-number":["PTC Therapeutics Germany GmbH"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Phenylketonuria (PKU) is a rare inherited metabolic disorder requiring lifelong management to prevent neurological, psychiatric, and physical complications. Although early detection through newborn screening has improved outcomes, real-world evidence on long-term care and healthcare utilisation remains limited. This study assessed the epidemiology, comorbidities, treatment practices, rehabilitation and healthcare resource utilisation (HCRU) of individuals with PKU in Germany, using nationwide statutory health insurance (SHI) claims data over ten years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Based on anonymised claims data of 16 SHI funds (~\u20094.4\u00a0million insured; 5% representative sample), 4,949\u20136,105 PKU patients were identified annually from 2013 to 2023, yielding a prevalence of 0.007%\u20130.008%. The five-year cumulative prevalence (2019\u20132023) was 0.010%, with a slight female predominance (52%). Compared to matched controls (1:10), PKU patients had higher odds of comorbidities, including intellectual disability (OR 16.0), other metabolic disorders (OR 9.2), osteoporosis (OR 3.4), hyperkinetic disorders (OR 2.1), and recurrent depressive disorders (OR 1.6), with the severity of cognitive impairment increasing with age. Less than 20% of the individuals received pharmacological treatment, with low incidences in patients older than 54 years. Nutritional therapy was common during childhood, adolescence and young adulthood (average 49% in ages 0\u201324) but declined with increasing age. Pregnancy terminations were documented in more than 15% of the 34 women with recorded pregnancy in the cohort. Rehabilitation care was overall higher than in the healthy population, especially among children aged 2\u201312 years (5.6% vs. 0.3% in controls), primarily for developmental disorders. Healthcare costs were considerably higher in the PKU cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>PKU care in Germany exhibits age-dependent differences in documented treatment patterns and a high burden of comorbidities, highlighting a substantial unmet medical need and the importance of structured lifelong management strategies.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-026-04467-3","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T15:13:31Z","timestamp":1783005211000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Care of patients with Phenylketonuria (PKU) in Germany \u2013 a claims data analysis from 2013 to 2023"],"prefix":"10.1186","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9370-4573","authenticated-orcid":false,"given":"Axel","family":"Boehnke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-2412-2752","authenticated-orcid":false,"given":"Lisa-Marie","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-3148-6517","authenticated-orcid":false,"given":"Constantin","family":"Heidecke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5693-9266","authenticated-orcid":false,"given":"Alexa","family":"Benson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4015-1623","authenticated-orcid":false,"given":"Aljoscha S.","family":"Neubauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2900-8378","authenticated-orcid":false,"given":"Ania C.","family":"Muntau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,2]]},"reference":[{"key":"4467_CR1","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","volume":"376","author":"N Blau","year":"2010","unstructured":"Blau N, van Spronsen FJ, Levy HL, Phenylketonuria. Lancet. 2010;376:1417\u201327. https:\/\/doi.org\/10.1016\/S0140-6736(10)60961-0.","journal-title":"Lancet"},{"key":"4467_CR2","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1186\/s13023-017-0685-2","volume":"12","author":"AMJ van Wegberg","year":"2017","unstructured":"van Wegberg AMJ, MacDonald A, Ahring K, B\u00e9langer-Quintana A, Blau N, Bosch AM, et al. The complete European guidelines on phenylketonuria: diagnosis and treatment. Orphanet J Rare Dis. 2017;12:162. https:\/\/doi.org\/10.1186\/s13023-017-0685-2.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR3","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13023-019-1153-y","volume":"14","author":"KF Trefz","year":"2019","unstructured":"Trefz KF, Muntau AC, Kohlscheen KM, Altevers J, Jacob C, Braun S, et al. Clinical burden of illness in patients with phenylketonuria (PKU) and associated comorbidities - a retrospective study of German health insurance claims data. Orphanet J Rare Dis. 2019;14:181. https:\/\/doi.org\/10.1186\/s13023-019-1153-y.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR4","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1007\/s10545-008-0918-6","volume":"31","author":"FJ van Spronsen","year":"2008","unstructured":"van Spronsen FJ, Burgard P. The truth of treating patients with phenylketonuria after childhood: the need for a new guideline. J Inherit Metab Dis. 2008;31:673\u20139. https:\/\/doi.org\/10.1007\/s10545-008-0918-6.","journal-title":"J Inherit Metab Dis"},{"key":"4467_CR5","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1007\/s004310051008","volume":"158","author":"P Burgard","year":"1999","unstructured":"Burgard P, Bremer HJ, B\u00fchrdel P, Clemens PC, M\u00f6nch E, Przyrembel H, et al. Rationale for the German recommendations for phenylalanine level control in phenylketonuria 1997. Eur J Pediatr. 1999;158:46\u201354. https:\/\/doi.org\/10.1007\/s004310051008.","journal-title":"Eur J Pediatr"},{"issue":"Suppl 2","key":"4467_CR6","doi-asserted-by":"publisher","first-page":"S415","DOI":"10.1007\/s10545-008-0978-7","volume":"31","author":"M Bik-Multanowski","year":"2008","unstructured":"Bik-Multanowski M, Didycz B, Mozrzymas R, Nowacka M, Kaluzny L, Cichy W, et al. Quality of life in noncompliant adults with phenylketonuria after resumption of the diet. J Inherit Metab Dis. 2008;31(Suppl 2):S415\u20138. https:\/\/doi.org\/10.1007\/s10545-008-0978-7.","journal-title":"J Inherit Metab Dis"},{"key":"4467_CR7","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s13023-016-0410-6","volume":"11","author":"U M\u00fctze","year":"2016","unstructured":"M\u00fctze U, Thiele AG, Baerwald C, Ceglarek U, Kiess W, Beblo S. Ten years of specialized adult care for phenylketonuria - a single-centre experience. Orphanet J Rare Dis. 2016;11:27. https:\/\/doi.org\/10.1186\/s13023-016-0410-6.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR8","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/S0140-6736(02)09334-0","volume":"360","author":"JH Walter","year":"2002","unstructured":"Walter JH, White FJ, Hall SK, MacDonald A, Rylance G, Boneh A, et al. How practical are recommendations for dietary control in phenylketonuria? Lancet. 2002;360:55\u20137. https:\/\/doi.org\/10.1016\/S0140-6736(02)09334-0.","journal-title":"Lancet"},{"key":"4467_CR9","unstructured":"European Medicines Agency (EMA). Kuvan | European Medicines Agency (EMA). 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/kuvan. Accessed 6 Aug 2025."},{"key":"4467_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2019.04.004","volume":"127","author":"AC Muntau","year":"2019","unstructured":"Muntau AC, Adams DJ, B\u00e9langer-Quintana A, Bushueva TV, Cerone R, Chien Y-H, et al. International best practice for the evaluation of responsiveness to sapropterin dihydrochloride in patients with phenylketonuria. Mol Genet Metab. 2019;127:1\u201311. https:\/\/doi.org\/10.1016\/j.ymgme.2019.04.004.","journal-title":"Mol Genet Metab"},{"key":"4467_CR11","doi-asserted-by":"publisher","first-page":"101459","DOI":"10.1016\/j.gim.2025.101459","volume":"27","author":"CO Harding","year":"2025","unstructured":"Harding CO, Whitehall KB, Lilienstein J, Sazova O, Lindstrom K, Levy DG, Burton BK. Long-term management strategies for pegvaliase use in phenylketonuria: Lessons learned from the phase-3 PRISM open-label extension study. Genet Med. 2025;27:101459. https:\/\/doi.org\/10.1016\/j.gim.2025.101459.","journal-title":"Genet Med"},{"key":"4467_CR12","doi-asserted-by":"publisher","first-page":"117739281985708","DOI":"10.1177\/1177392819857089","volume":"13","author":"T Hydery","year":"2019","unstructured":"Hydery T, Coppenrath VA. A Comprehensive Review of Pegvaliase, an Enzyme Substitution Therapy for the Treatment of Phenylketonuria. Drug Target Insights. 2019;13:1177392819857089. https:\/\/doi.org\/10.1177\/1177392819857089.","journal-title":"Drug Target Insights"},{"key":"4467_CR13","doi-asserted-by":"publisher","first-page":"107564","DOI":"10.1016\/j.ymgme.2023.107564","volume":"139","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Baerwald C, Heimbold C, Kamrath C, Parhofer KG, Reichert A, et al. Two years of pegvaliase in Germany: Experiences and best practice recommendations. Mol Genet Metab. 2023;139:107564. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107564.","journal-title":"Mol Genet Metab"},{"key":"4467_CR14","doi-asserted-by":"publisher","first-page":"1488215","DOI":"10.3389\/fendo.2025.1488215","volume":"16","author":"B Hanusch","year":"2025","unstructured":"Hanusch B, Schlegtendal A, Grasemann C, L\u00fccke T, Sinningen K. Adults with Phenylketonuria have suboptimal bone mineral density apart from vitamin D and calcium sufficiency. Front Endocrinol (Lausanne). 2025;16:1488215. https:\/\/doi.org\/10.3389\/fendo.2025.1488215.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"4467_CR15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.ymgme.2012.07.006","volume":"107","author":"LC Burrage","year":"2012","unstructured":"Burrage LC, McConnell J, Haesler R, O\u2019Riordan MA, Sutton VR, Kerr DS, McCandless SE. High prevalence of overweight and obesity in females with phenylketonuria. Mol Genet Metab. 2012;107:43\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2012.07.006.","journal-title":"Mol Genet Metab"},{"key":"4467_CR16","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ymgme.2018.09.006","volume":"125","author":"BK Burton","year":"2018","unstructured":"Burton BK, Jones KB, Cederbaum S, Rohr F, Waisbren S, Irwin DE, et al. Prevalence of comorbid conditions among adult patients diagnosed with phenylketonuria. Mol Genet Metab. 2018;125:228\u201334. https:\/\/doi.org\/10.1016\/j.ymgme.2018.09.006.","journal-title":"Mol Genet Metab"},{"key":"4467_CR17","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1016\/j.ymgme.2015.06.010","volume":"115","author":"V Crujeiras","year":"2015","unstructured":"Crujeiras V, Ald\u00e1miz-Echevarr\u00eda L, Dalmau J, Vitoria I, Andrade F, Roca I, et al. Vitamin and mineral status in patients with hyperphenylalaninemia. Mol Genet Metab. 2015;115:145\u201350. https:\/\/doi.org\/10.1016\/j.ymgme.2015.06.010.","journal-title":"Mol Genet Metab"},{"key":"4467_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/nu13103443","author":"C Rodrigues","year":"2021","unstructured":"Rodrigues C, Pinto A, Faria A, Teixeira D, van Wegberg AMJ, Ahring K, et al. Is the Phenylalanine-Restricted Diet a Risk Factor for Overweight or Obesity in Patients with Phenylketonuria (PKU)? A Systematic Review and Meta-Analysis. Nutrients. 2021. https:\/\/doi.org\/10.3390\/nu13103443.","journal-title":"Nutrients"},{"key":"4467_CR19","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1186\/s13023-023-02636-2","volume":"18","author":"AT Tankeu","year":"2023","unstructured":"Tankeu AT, Pavlidou DC, Superti-Furga A, Gariani K, Tran C. Overweight and obesity in adult patients with phenylketonuria: a systematic review. Orphanet J Rare Dis. 2023;18:37. https:\/\/doi.org\/10.1186\/s13023-023-02636-2.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR20","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1186\/s13023-021-02108-5","volume":"16","author":"C Rohde","year":"2021","unstructured":"Rohde C, Thiele AG, Baerwald C, Ascherl RG, Lier D, Och U, et al. Preventing maternal phenylketonuria (PKU) syndrome: important factors to achieve good metabolic control throughout pregnancy. Orphanet J Rare Dis. 2021;16:477. https:\/\/doi.org\/10.1186\/s13023-021-02108-5.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR21","doi-asserted-by":"publisher","unstructured":"Gautiero C, Scala I, Esposito G, Coppola MR, Cacciapuoti N, Fisco M, et al. The light and the dark side of maternal PKU: single-centre experience of dietary management and emergency treatment protocol of unplanned pregnancies. Nutrients. 2025. https:\/\/doi.org\/10.3390\/nu17061048.","DOI":"10.3390\/nu17061048"},{"key":"4467_CR22","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1177\/10497323241266750","volume":"35","author":"C Harris","year":"2025","unstructured":"Harris C, Larkin M, Walker A-M, Johnson G. The Experience of Phenylketonuria in Pregnancy and the Developing Maternal-Infant Relationship: A Qualitative Study. Qual Health Res. 2025;35:88\u2013101. https:\/\/doi.org\/10.1177\/10497323241266750.","journal-title":"Qual Health Res"},{"key":"4467_CR23","doi-asserted-by":"publisher","first-page":"100764","DOI":"10.1016\/j.ymgmr.2021.100764","volume":"27","author":"F Trefz","year":"2021","unstructured":"Trefz F, Muntau AC, Schneider KM, Altevers J, Jacob C, Braun S, et al. Health economic burden of patients with phenylketonuria (PKU) - A retrospective study of German health insurance claims data. Mol Genet Metab Rep. 2021;27:100764. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100764.","journal-title":"Mol Genet Metab Rep"},{"key":"4467_CR24","doi-asserted-by":"publisher","first-page":"101134","DOI":"10.1016\/j.ymgmr.2024.101134","volume":"41","author":"J-B Arnoux","year":"2024","unstructured":"Arnoux J-B, Douillard C, Maillot F, Bou\u00e9e S, Jacob C, Schneider KM, et al. Health economic impact of patients with phenylketonuria (PKU) in France - A nationwide study of health insurance claims data. Mol Genet Metab Rep. 2024;41:101134. https:\/\/doi.org\/10.1016\/j.ymgmr.2024.101134.","journal-title":"Mol Genet Metab Rep"},{"key":"4467_CR25","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ymgme.2013.05.003","volume":"109","author":"I Eijgelshoven","year":"2013","unstructured":"Eijgelshoven I, Demirdas S, Smith TA, van Loon JMT, Latour S, Bosch AM. The time consuming nature of phenylketonuria: a cross-sectional study investigating time burden and costs of phenylketonuria in the Netherlands. Mol Genet Metab. 2013;109:237\u201342. https:\/\/doi.org\/10.1016\/j.ymgme.2013.05.003.","journal-title":"Mol Genet Metab"},{"key":"4467_CR26","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgmr.2016.08.008","volume":"9","author":"A MacDonald","year":"2016","unstructured":"MacDonald A, Smith TA, de Silva S, Alam V, van Loon JMT. The personal burden for caregivers of children with phenylketonuria: A cross-sectional study investigating time burden and costs in the UK. Mol Genet Metab Rep. 2016;9:1\u20135. https:\/\/doi.org\/10.1016\/j.ymgmr.2016.08.008.","journal-title":"Mol Genet Metab Rep"},{"key":"4467_CR27","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/s10545-016-9995-0","volume":"40","author":"L Wang","year":"2017","unstructured":"Wang L, Zou H, Ye F, Wang K, Li X, Chen Z, et al. Household financial burden of phenylketonuria and its impact on treatment in China: a cross-sectional study. J Inherit Metab Dis. 2017;40:369\u201376. https:\/\/doi.org\/10.1007\/s10545-016-9995-0.","journal-title":"J Inherit Metab Dis"},{"key":"4467_CR28","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.ymgmr.2018.10.002","volume":"17","author":"S Ford","year":"2018","unstructured":"Ford S, O\u2019Driscoll M, MacDonald A. Living with Phenylketonuria: Lessons from the PKU community. Mol Genet Metab Rep. 2018;17:57\u201363. https:\/\/doi.org\/10.1016\/j.ymgmr.2018.10.002.","journal-title":"Mol Genet Metab Rep"},{"key":"4467_CR29","doi-asserted-by":"publisher","unstructured":"Krampe J, Melnik S, Puschmann J, Leppert B. Utilizing claims data for health service research: an examination of extrapolation strategies of German SHI data. In: 23rd Deutscher Kongress f\u00fcr Versorgungsforschung (DKVF); 2024. https:\/\/doi.org\/10.3205\/24dkvf055.","DOI":"10.3205\/24dkvf055"},{"key":"4467_CR30","unstructured":"Orphanet, INSERM US14. Phenylketonuria (ORPHA:716) [Internet]. Paris: Orphanet; 2026 [cited 2026 May 26]. Available from: https:\/\/www.orpha.net\/en\/disease\/detail\/716?name=phenylketonuria&mode=name."},{"key":"4467_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ymgme.2017.03.002","volume":"121","author":"DA Bilder","year":"2017","unstructured":"Bilder DA, Kobori JA, Cohen-Pfeffer JL, Johnson EM, Jurecki ER, Grant ML. Neuropsychiatric comorbidities in adults with phenylketonuria: A retrospective cohort study. Mol Genet Metab. 2017;121:1\u20138. https:\/\/doi.org\/10.1016\/j.ymgme.2017.03.002.","journal-title":"Mol Genet Metab"},{"key":"4467_CR32","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1198\/sbr.2009.0049","volume":"2","author":"X Yan","year":"2010","unstructured":"Yan X, Su XG. Stratified Wilson and Newcombe Confidence Intervals for Multiple Binomial Proportions. Stat Biopharm Res. 2010;2:329\u201335. https:\/\/doi.org\/10.1198\/sbr.2009.0049.","journal-title":"Stat Biopharm Res"},{"key":"4467_CR33","doi-asserted-by":"publisher","first-page":"e297","DOI":"10.1371\/journal.pmed.0040297","volume":"4","author":"JP Vandenbroucke","year":"2007","unstructured":"Vandenbroucke JP, von Elm E, Altman DG, G\u00f8tzsche PC, Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med. 2007;4:e297. https:\/\/doi.org\/10.1371\/journal.pmed.0040297.","journal-title":"PLoS Med"},{"key":"4467_CR34","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1055\/s-0042-112008","volume":"78","author":"E Swart","year":"2016","unstructured":"Swart E, Bitzer EM, Gothe H, Harling M, Hoffmann F, Horenkamp-Sonntag D, et al. STandardisierte BerichtsROutine f\u00fcr Sekund\u00e4rdaten Analysen (STROSA) - ein konsentierter Berichtsstandard f\u00fcr Deutschland, Version 2. [A Consensus German Reporting Standard for Secondary Data Analyses, Version 2 (STROSA-STandardisierte BerichtsROutine f\u00fcr Sekund\u00e4rdatenAnalysen)]. Gesundheitswesen. 2016;78:e161. https:\/\/doi.org\/10.1055\/s-0042-112008.","journal-title":"Gesundheitswesen"},{"key":"4467_CR35","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1055\/s-0034-1396815","volume":"77","author":"E Swart","year":"2015","unstructured":"Swart E, Gothe H, Geyer S, Jaunzeme J, Maier B, Grobe TG, Ihle P. Gute Praxis Sekund\u00e4rdatenanalyse (GPS): Leitlinien und Empfehlungen. [Good Practice of Secondary Data Analysis (GPS): guidelines and recommendations]. Gesundheitswesen. 2015;77:120\u20136. https:\/\/doi.org\/10.1055\/s-0034-1396815.","journal-title":"Gesundheitswesen"},{"key":"4467_CR36","unstructured":"Statistisches Bundesamt. Schwangerschaftsabbr\u00fcche (Abtreibungen) in Deutschland. 09.09.2019. https:\/\/www.destatis.de\/DE\/Themen\/Gesellschaft-Umwelt\/Gesundheit\/Schwangerschaftsabbrueche\/_inhalt.html#235870. Accessed 6 Aug 2025."},{"key":"4467_CR37","doi-asserted-by":"publisher","unstructured":"Rohde C, Thiele AG, Tomm A, Lier D, Eschrich K, Baerwald C, Beblo S. The prevention of maternal phenylketonuria (PKU) syndrome: the development and evaluation of a specific training program. Nutrients. 2024. https:\/\/doi.org\/10.3390\/nu16234111.","DOI":"10.3390\/nu16234111"},{"key":"4467_CR38","doi-asserted-by":"publisher","first-page":"107625","DOI":"10.1016\/j.ymgme.2023.107625","volume":"139","author":"S Charri\u00e8re","year":"2023","unstructured":"Charri\u00e8re S, Maillot F, Bou\u00e9e S, Douillard C, Jacob C, Schneider KM, et al. Health status and comorbidities of adult patients with phenylketonuria (PKU) in France with a focus on early-diagnosed patients - A nationwide study of health insurance claims data. Mol Genet Metab. 2023;139:107625. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107625.","journal-title":"Mol Genet Metab"},{"key":"4467_CR39","doi-asserted-by":"publisher","first-page":"107704","DOI":"10.1016\/j.ymgme.2023.107704","volume":"140","author":"C Douillard","year":"2023","unstructured":"Douillard C, Arnoux J-B, Bou\u00e9e S, Jacob C, Schneider KM, Theil J, et al. Health status and comorbidities of adult patients with late-diagnosed phenylketonuria (PKU) born before the newborn screening in France - A nationwide study of health insurance claims data. Mol Genet Metab. 2023;140:107704. https:\/\/doi.org\/10.1016\/j.ymgme.2023.107704.","journal-title":"Mol Genet Metab"},{"key":"4467_CR40","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-020-01407-7","volume":"15","author":"S Hopf","year":"2020","unstructured":"Hopf S, Nowak C, Hennermann JB, Schmidtmann I, Pfeiffer N, Pitz S. Saccadic reaction time and ocular findings in phenylketonuria. Orphanet J Rare Dis. 2020;15:124. https:\/\/doi.org\/10.1186\/s13023-020-01407-7.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR41","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1186\/s13023-024-03203-z","volume":"19","author":"KB Whitehall","year":"2024","unstructured":"Whitehall KB, Rose S, Clague GE, Ahring KK, Bilder DA, Harding CO, et al. Systematic literature review of the somatic comorbidities experienced by adults with phenylketonuria. Orphanet J Rare Dis. 2024;19:293. https:\/\/doi.org\/10.1186\/s13023-024-03203-z.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR42","doi-asserted-by":"publisher","first-page":"561","DOI":"10.3389\/fpsyt.2019.00561","volume":"10","author":"K Ashe","year":"2019","unstructured":"Ashe K, Kelso W, Farrand S, Panetta J, Fazio T, de Jong G. Psychiatric and Cognitive Aspects of Phenylketonuria: The Limitations of Diet and Promise of New Treatments. Front Psychiatry. 2019;10:561. https:\/\/doi.org\/10.3389\/fpsyt.2019.00561.","journal-title":"Front Psychiatry"},{"key":"4467_CR43","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1097\/DBP.0000000000000072","volume":"35","author":"A Clacy","year":"2014","unstructured":"Clacy A, Sharman R, McGill J. Depression, anxiety, and stress in young adults with phenylketonuria: associations with biochemistry. J Dev Behav Pediatr. 2014;35:388\u201391. https:\/\/doi.org\/10.1097\/DBP.0000000000000072.","journal-title":"J Dev Behav Pediatr"},{"key":"4467_CR44","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1037\/neu0000358","volume":"31","author":"R Jahja","year":"2017","unstructured":"Jahja R, Huijbregts SCJ, de Sonneville LMJ, van der Meere JJ, Legemaat AM, Bosch AM, et al. Cognitive profile and mental health in adult phenylketonuria: A PKU-COBESO study. Neuropsychology. 2017;31:437\u201347. https:\/\/doi.org\/10.1037\/neu0000358.","journal-title":"Neuropsychology"},{"key":"4467_CR45","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/gim.2013.157","volume":"16","author":"J Vockley","year":"2014","unstructured":"Vockley J, Andersson HC, Antshel KM, Braverman NE, Burton BK, Frazier DM, et al. Phenylalanine hydroxylase deficiency: diagnosis and management guideline. Genet Med. 2014;16:188\u2013200. https:\/\/doi.org\/10.1038\/gim.2013.157.","journal-title":"Genet Med"},{"key":"4467_CR46","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1002\/jimd.12186","volume":"43","author":"ERLC Vardy","year":"2020","unstructured":"Vardy ERLC, MacDonald A, Ford S, Hofman DL. Phenylketonuria, co-morbidity, and ageing: A review. J Inherit Metab Dis. 2020;43:167\u201378. https:\/\/doi.org\/10.1002\/jimd.12186.","journal-title":"J Inherit Metab Dis"},{"key":"4467_CR47","doi-asserted-by":"publisher","unstructured":"Hoedt AE ten, de Sonneville LMJ, Francois B, Horst NM, ter, Janssen MCH, Rubio-Gozalbo ME, et al. High phenylalanine levels directly affect mood and sustained attention in adults with phenylketonuria: a randomised, double-blind, placebo-controlled, crossover trial. J Inherit Metab Dis. 2011;34:165\u201371. https:\/\/doi.org\/10.1007\/s10545-010-9253-9.","DOI":"10.1007\/s10545-010-9253-9"},{"key":"4467_CR48","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1007\/s00103-020-03168-x","volume":"63","author":"KA Schiergens","year":"2020","unstructured":"Schiergens KA, Wei\u00df KJ, Dokoupil K, Fleissner S, Maier EM. Ern\u00e4hrung bei angeborenen Stoffwechselerkrankungen \u2013 ein Spagat zwischen Genuss und Therapie. [Dietary treatment of inborn errors of metabolism-a balancing act between indulgence and therapy]. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2020;63:864\u201371. https:\/\/doi.org\/10.1007\/s00103-020-03168-x.","journal-title":"Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz"},{"key":"4467_CR49","doi-asserted-by":"publisher","first-page":"155116","DOI":"10.1016\/j.metabol.2021.155116","volume":"128","author":"D Bratkovic","year":"2022","unstructured":"Bratkovic D, Margvelashvili L, Tchan MC, Nisbet J, Smith N. PTC923 (sepiapterin) lowers elevated blood phenylalanine in subjects with phenylketonuria: a phase 2 randomized, multi-center, three-period crossover, open-label, active controlled, all-comers study. Metabolism. 2022;128:155116. https:\/\/doi.org\/10.1016\/j.metabol.2021.155116.","journal-title":"Metabolism"},{"key":"4467_CR50","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.ymgme.2018.03.006","volume":"124","author":"J Thomas","year":"2018","unstructured":"Thomas J, Levy H, Amato S, Vockley J, Zori R, Dimmock D, et al. Pegvaliase for the treatment of phenylketonuria: Results of a long-term phase 3 clinical trial program (PRISM). Mol Genet Metab. 2018;124:27\u201338. https:\/\/doi.org\/10.1016\/j.ymgme.2018.03.006.","journal-title":"Mol Genet Metab"},{"key":"4467_CR51","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1016\/j.ymgme.2019.05.006","volume":"128","author":"O Hausmann","year":"2019","unstructured":"Hausmann O, Daha M, Longo N, Knol E, M\u00fcller I, Northrup H, Brockow K, Pegvaliase. Immunological profile and recommendations for the clinical management of hypersensitivity reactions in patients with phenylketonuria treated with this enzyme substitution therapy. Mol Genet Metab. 2019;128:84\u201391. https:\/\/doi.org\/10.1016\/j.ymgme.2019.05.006.","journal-title":"Mol Genet Metab"},{"key":"4467_CR52","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1038\/s41436-018-0403-z","volume":"21","author":"N Longo","year":"2019","unstructured":"Longo N, Dimmock D, Levy H, Viau K, Bausell H, Bilder DA, et al. Evidence- and consensus-based recommendations for the use of pegvaliase in adults with phenylketonuria. Genet Med. 2019;21:1851\u201367. https:\/\/doi.org\/10.1038\/s41436-018-0403-z.","journal-title":"Genet Med"},{"key":"4467_CR53","doi-asserted-by":"publisher","first-page":"101405","DOI":"10.1016\/j.gim.2025.101405","volume":"27","author":"S Shrestha","year":"2025","unstructured":"Shrestha S, Zagel AL, Pillai NR, Ahmed A, Jacobson J, Ranasinghe A, et al. Pegvaliase therapy for phenylketonuria: Real-world safety, efficacy, and medication access outcomes in a pharmacist-led pegvaliase program. Genet Med. 2025;27:101405. https:\/\/doi.org\/10.1016\/j.gim.2025.101405.","journal-title":"Genet Med"},{"key":"4467_CR54","doi-asserted-by":"publisher","first-page":"100790","DOI":"10.1016\/j.ymgmr.2021.100790","volume":"28","author":"D Adams","year":"2021","unstructured":"Adams D, Andersson HC, Bausell H, Crivelly K, Eggerding C, Lah M, et al. Use of pegvaliase in the management of phenylketonuria: Case series of early experience in US clinics. Mol Genet Metab Rep. 2021;28:100790. https:\/\/doi.org\/10.1016\/j.ymgmr.2021.100790.","journal-title":"Mol Genet Metab Rep"},{"key":"4467_CR55","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1016\/S0140-6736(24)01556-3","volume":"404","author":"AC Muntau","year":"2024","unstructured":"Muntau AC, Longo N, Ezgu F, Schwartz IVD, Lah M, Bratkovic D, et al. Effects of oral sepiapterin on blood Phe concentration in a broad range of patients with phenylketonuria (APHENITY): results of an international, phase 3, randomised, double-blind, placebo-controlled trial. Lancet. 2024;404:1333\u201345. https:\/\/doi.org\/10.1016\/S0140-6736(24)01556-3.","journal-title":"Lancet"},{"key":"4467_CR56","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1186\/s13023-020-01391-y","volume":"15","author":"A MacDonald","year":"2020","unstructured":"MacDonald A, van Wegberg AMJ, Ahring K, Beblo S, B\u00e9langer-Quintana A, Burlina A, et al. PKU dietary handbook to accompany PKU guidelines. Orphanet J Rare Dis. 2020;15:171. https:\/\/doi.org\/10.1186\/s13023-020-01391-y.","journal-title":"Orphanet J Rare Dis"},{"key":"4467_CR57","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.clnu.2009.03.004","volume":"28","author":"K Ahring","year":"2009","unstructured":"Ahring K, B\u00e9langer-Quintana A, Dokoupil K, Gokmen Ozel H, Lammardo AM, MacDonald A, et al. Dietary management practices in phenylketonuria across European centres. Clin Nutr. 2009;28:231\u20136. https:\/\/doi.org\/10.1016\/j.clnu.2009.03.004.","journal-title":"Clin Nutr"},{"key":"4467_CR58","doi-asserted-by":"publisher","DOI":"10.3390\/nu15204352","author":"F Ilgaz","year":"2023","unstructured":"Ilgaz F, Ford S, O\u2019Driscoll MF, MacDonald A. Adult PKU Clinics in the UK-Users\u2019 Experiences and Perspectives. Nutrients. 2023. https:\/\/doi.org\/10.3390\/nu15204352.","journal-title":"Nutrients"},{"key":"4467_CR59","doi-asserted-by":"publisher","unstructured":"Jentsch A, Straka D, Ramminger S, Valentini L. Aktueller Versorgungszustand erwachsener Phenylketonurie (PKU) Patienten in Deutschland. Ern\u00e4hrung \u2013Gewissheit im Fluss! 16\u201318 May 2019; Bregenz. Georg Thieme Verlag KG; 2019. https:\/\/doi.org\/10.1055\/s-0039-1684889.","DOI":"10.1055\/s-0039-1684889"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-026-04467-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-026-04467-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T12:13:42Z","timestamp":1783080822000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13023-026-04467-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,2]]},"references-count":59,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4467"],"URL":"https:\/\/doi.org\/10.1186\/s13023-026-04467-3","relation":{},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,2]]},"assertion":[{"value":"14 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ABo is a full-time employee of PTC Therapeutics Germany GmbH. CH, LMM, and ABe are full-time employees of Gesundheitsforen Leipzig GmbH. ASN is affiliated with Neubauer Consult \/ IfGPh Institut f\u00fcr Gesundheits- und Pharmako\u00f6konomie GmbH. ACM received no financial compensation for her contribution. All authors declare that they have no other competing interests related to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"237"}}